Summary:
This study aims to assess the efficacy, safety, and tolerability of itepekimab in chronic obstructive pulmonary disease (COPD) patients.
Criteria:- Must be 40-85 years of age at the time of consent
- Former Smoker or have quit smoking within the last 6 months before consenting to the study
- Must have had at least 1 COPD flare-up in the last 12 months and prescribed a steroid (i.e.: prednisone, Solu-Medrol, and or an antibiotic)
- Must have used maintenance inhalers for greater than 3 months prior to consenting to the study
- Willing to sign an informed consent to participate in the study
Qualified Participants May Receive:
- $100 per completed study visit up to 31 clinic visits
- Study visit transportation at no cost to you
- Medical treatment at no cost to you